BRiTE – Adaptin Bio

BRiTE

Adaptin Bio, Inc., a Lucius Partners Portfolio Company, Completes Alternative Public Offering (APO) and Closes $7.7 Million Private Placement
Continue reading
Adaptin Bio Announces FDA Clearance of IND Application for APTN-101 in Glioblastoma
APTN-101 is a novel BRiTE therapeutic targeting the most aggressive [...]

Continue reading

This website uses cookies and third party services. See our privacy policy here. Customize settings OK Reject

Tracking Cookies

YouTube
Vimeo
Facebook
X
Google Maps